# Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

> **NCT00643045** · PHASE3 · COMPLETED · sponsor: **Newron Pharmaceuticals SPA** · enrollment: 269 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** Safinamide
- **DRUG:** Safinamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00643045
- **Lead sponsor:** Newron Pharmaceuticals SPA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2006-01
- **Final completion:** 2007-07
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2008-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00643045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00643045, "Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00643045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*